Last updated: September 2026
This consent describes the risks, benefits, and alternatives of treatment with GLP-1 receptor agonist medications (such as semaglutide) and GLP-1/GIP dual agonists (such as tirzepatide) for weight management. Read it fully before consenting.
GLP-1 medications mimic natural gut hormones that regulate appetite and blood sugar. When prescribed for weight management, they are used together with a reduced-calorie diet and increased physical activity. They are typically administered as a once-weekly subcutaneous injection with a dose that is gradually increased ("titrated") over several months.
Semaglutide and tirzepatide carry an FDA boxed warning: in rodent studies these medications caused thyroid C-cell tumors. It is unknown whether they cause medullary thyroid carcinoma (MTC) in humans. Do not use these medications if you or a family member has a history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider immediately if you develop a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
GLP-1 medications may cause fetal harm and must not be used during pregnancy or while breastfeeding. Discontinue at least 2 months before a planned pregnancy. Weight loss and these medications may also reduce the effectiveness of oral contraceptives in some cases (particularly with tirzepatide) — discuss contraception with your provider.
If your provider prescribes a compounded form of semaglutide or tirzepatide, you understand that compounded drugs are prepared by state-licensed compounding pharmacies for an individual patient and are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed. Compounded medications may differ from FDA-approved products. FDA-approved alternatives (e.g., Wegovy®, Zepbound®) exist and may be available to you through other channels; discuss options with your provider.
Alternatives to GLP-1 therapy include lifestyle modification alone (diet, exercise, behavioral therapy), other prescription weight-management medications, bariatric surgery, and no treatment. Your provider can discuss these options with you.
By checking the GLP-1 Medication Informed Consent box during intake, you confirm that you have read and understood the above; that no specific weight-loss outcome has been promised to you; that you have had the opportunity to ask questions; and that you consent to GLP-1 treatment if, and only if, a licensed provider determines it is appropriate for you.